Investor Presentation

View our latest Investor Presentation to find the most recent investor-related information

Algernon Pharmaceuticals DMT/Stroke Clinical Program

Watch Here

Company Overview

Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Stock Snapshot

Investor Contact Information


Algernon Pharmaceuticals Inc.
601 West Broadway
Suite 400
Vancouver, BC V5Z 4C2
T: 604-398-4175

Investor Relations

Christopher Moreau
Chief Executive Officer
T: 604-398-4175

Transfer Agent

TSX Trust Company
1066 W. Hastings Street
Suite 1600
Vancouver, BC V6E 3X1
T: 604-235-3700